Gary Dukart

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Michael B. Atkins, Manuel Hidalgo, Walter M. Stadler et al. · Journal of Clinical Oncology · 2004 · 943 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose

Keith A. Rodvold, Mark H. Gotfried, Mary Cwik et al. · Journal of Antimicrobial Chemotherapy · 2006 · 303 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia

Antonio Freire, Vasyl Melnyk, Min Ja Kim et al. · Diagnostic Microbiology and Infectious Disease · 2010 · 287 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.

I. Craig Henderson, Joseph C. Allegra, Thomas Woodcock et al. · Journal of Clinical Oncology · 1989 · 247 citations

Medicine, Oncology, Pharmacology +13

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

Manuel Hidalgo, Jan C. Buckner, Charles Erlichman et al. · Clinical Cancer Research · 2006 · 210 citations

Medicine, Oncology, Pharmacology +17